← Back to Search

Serotonin-Norepinephrine Reuptake Inhibitor

A for Menopause (DVS Trial)

Phase 3
Waitlist Available
Led By Claudio N Soares, MD, PhD
Research Sponsored by Hamilton Health Sciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
men and women, aged 40-60 years
diagnosis of MDD
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

DVS Trial Summary

The main objective of this study is to characterize a range of brain activation symptoms associated with depression and response to treatment in midlife men and women with MDD, using MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes and night sweats). Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.

Eligible Conditions
  • Depression
  • Menopause

DVS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

DVS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effects of desvenlafaxine succinate (DVS) on brain structure and activation in midlife men and women with MDD.
Secondary outcome measures
Changes in brain activity
Changes in menopause-related symptoms among females

Side effects data

From 2015 Phase 4 trial • 53 Patients • NCT01916824
21%
Headache
17%
Insomnia
13%
Upper Respiratory Tract Infection
8%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Participants With Major Depressive Disorder
Healthy Controls

DVS Trial Design

1Treatment groups
Experimental Treatment
Group I: AExperimental Treatment1 Intervention
Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Desvenlafaxine
FDA approved

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationLead Sponsor
365 Previous Clinical Trials
300,713 Total Patients Enrolled
Wyeth is now a wholly owned subsidiary of PfizerIndustry Sponsor
625 Previous Clinical Trials
248,349 Total Patients Enrolled
6 Trials studying Menopause
1,559 Patients Enrolled for Menopause
St. Joseph's Healthcare HamiltonOTHER
195 Previous Clinical Trials
25,334 Total Patients Enrolled
2 Trials studying Menopause
57 Patients Enrolled for Menopause

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025